FDA inspection
Novartis Pharma S.A.S. - Centre de Biotechnologie: FDA inspection ending May 23, 2025
FDA inspection 1315626 · Voluntary Action Indicated (VAI) · Huningue
Key facts
| Inspection ID | 1315626 |
|---|---|
| Firm | Novartis Pharma S.A.S. - Centre de Biotechnologie |
| FEI number | 3004864869 |
| Address | 8 rue de l Industrie, BP 355 |
| City | Huningue |
| Country | France |
| Fiscal year | 2025 |
| Inspection end date | May 23, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data